phenazine biosynthesis like protein domain containingGenealiases: HEL-S-306 · MAWBP · MAWDBP
Q-omics provides the consensus-scored PBLD profile across patient tissues and cancer cell-line models. PBLD expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PBLD is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PBLD protein abundance shows 28,427 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where PBLD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PBLD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PBLD survival associations across molecular data types. PBLD RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PBLD RNA expression–survival associations across cancer types. High PBLD expression shows unfavorable associations in UVM and BLCA, but favorable associations in KIRC, KIRP, LGG and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PBLD RNA expression.
This table summarizes PBLD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PBLD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PBLD shows lower tumor expression in COAD, KICH, KIRP, LIHC, BLCA and KIRC. The COAD box plot shows higher PBLD RNA expression in normal versus tumor tissue (log2 FC = −2.692, t-test p < 0.001).
This table shows molecular features associated with PBLD in patient tissues and cancer cell lines. In patient samples, PBLD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PBLD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
